A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Collaborators: Jiangxi Provincial Cancer Hospital; Jilin University; Shanghai 10th People's Hospital; Shanghai Tongji Hospital, Tongji University School of Medicine
• Treatments: Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Oxaliplatin

Criteria

Inclusion Criteria:

• Age ≤ 75 years with histologically proven NSCLC

• No severe major organ dysfunction

• WHO performance status of 0 or 1

• No prior cancer chemotherapy

• A Clinical Stage ≥ IA (T1a, N0, M0) of lung disease but without diagnosed distant metastasis (according to the 1997 revision of the International Union Against Cancer TNM staging system) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan.

Exclusion Criteria:

• Age ≥ 76

• Severe major organ dysfunction

• WHO performance status of >1

• Prior cancer chemotherapy

• Stage IV